5月11日夜盘，生物科技公司百济神州（ONC）股价大跌5.63%，引发市场关注。这一跌势可能与公司重要股东近期的减持行为以及公司面临的激烈市场竞争有关。
据悉，百济神州的两个重要股东近期进行了大规模减持。高瓴资本自2023年四季度以来累计减持超过420万股，持股比例显著下降。同时，Baker Brother Advisors也从2023年四季度开始减持，累计减持287.23万股，持股比例从11.03%降至8.21%。这些长期投资者的减持行为引发了市场对公司未来发展前景的担忧。
此外，百济神州在其核心产品市场面临日益激烈的竞争。公司的主打产品泽布替尼在BTK抑制剂市场上虽然表现强劲，但面临来自第三代BTK抑制剂的潜在威胁。同时，公司的PD-1抑制剂百泽安在国内外市场都面临激烈竞争，增长空间受限。投资者可能担心，尽管公司近期业绩亮眼，但当前估值已经充分反映了这些积极因素，而未来增长面临不确定性。这些因素综合导致了投资者信心的动摇，引发了股价的大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.